MWNA
OVID icon

Marshall Wace North America’s Ovid Therapeutics OVID Stock Holding History

Marshall Wace North America’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-12,735
Closed -$41K – 1514
2019
Q3 		$41K Buy
+12,735
New +$28.9K ﹤0.01% 1183

Other funds holding OVID

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Marshall Wace North America's OVID Position: Q4 2019 in Review

Marshall Wace North America sold out of Ovid Therapeutics (OVID) in Q4 2019, closing a stake of 12,735 shares — an estimated $41K sold.

Marshall Wace North America first reported a position in OVID in Q3 2019 and held it in 1 quarter. The position peaked at $41K in Q3 2019. 62 funds tracked by Wall St. Rank hold OVID as of Q4 2019.

  • Marshall Wace North America reported no remaining Ovid Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Marshall Wace North America sold 12,735 Ovid Therapeutics shares in Q4 2019, an estimated $41K.
  • Marshall Wace North America first reported a position in Ovid Therapeutics in Q3 2019 and held it in 1 quarter.
  • Marshall Wace North America's Ovid Therapeutics position peaked at $41K in Q3 2019.
  • 62 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q4 2019.

Based on Marshall Wace North America's 13F filing for Q4 2019, filed 14 Feb 2020.